Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine

Vaccine. 2013 Aug 2;31(35):3585-93. doi: 10.1016/j.vaccine.2013.05.010. Epub 2013 May 18.


Background: The currently recommended single dose of the 23-valent pneumococcal free polysaccharide vaccine (PPSV23) for adults 65 years of age and older does not provide extended protection into older age. This reflects a significant unmet medical need for alternative strategies to protect older adults against pneumococcal infection, which may be met by the 13-valent polysaccharide conjugate vaccine (PCV13).

Methods: We performed a randomized, modified double-blind trial in 936 adults aged 70 years and older who had previously received PPSV23 at least 5 years before study entry and were now vaccinated with PCV13 or PPSV23. At 1 year after enrollment, all subjects received a follow-on dose of PCV13. Anti-pneumococcal opsonophagocytic activity (OPA) titers were measured before and at 1 month after each vaccination.

Results: Following the enrollment vaccination, OPA titers were significantly greater in the PCV13 group compared to the PPSV23 group for 10 of the 12 serotypes common to both vaccines and to serotype 6A which is unique to PCV13. Responses were noninferior for the other 2 common serotypes. Responses to PCV13 given at 1 year were generally lower in the group that received PPSV23 at enrollment.

Conclusion: In adults aged 70 years and older previously vaccinated with PPSV23, PCV13 was significantly more immunogenic than PPSV23 for most of the common serotypes and for serotype 6A. The OPA responses after a follow-on dose of PCV13 one year later indicate that a prior dose of PPSV23, but not PCV13, diminishes the response to the subsequent administration of PCV13.

Keywords: 13-valent pneumococcal conjugate vaccine; 23-valent polysaccharide vaccine; ACIP; AE; Adults; CI; CRM(197); GMR; GMT; ITP; OPA; PCV; PCV13; PPSV23; Pneumococcal conjugate vaccine; RCDC; SAE; United States Advisory Committee on Immunization Practices; adverse event; confidence interval; cross-reactive material 197; geometric mean ratio; geometric mean titer; idiopathic thrombocytopenic purpura; opsonophagocytic activity; pneumococcal polysaccharide conjugate vaccine; reverse cumulative distribution curve; serious adverse event.

Publication types

  • Clinical Trial, Phase III
  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Aged, 80 and over
  • Antibodies, Bacterial / blood
  • Double-Blind Method
  • Female
  • Humans
  • Immunization, Secondary*
  • Male
  • Pneumococcal Vaccines* / adverse effects
  • Pneumococcal Vaccines* / immunology
  • Pneumococcal Vaccines* / therapeutic use
  • Pneumonia, Pneumococcal / immunology
  • Pneumonia, Pneumococcal / prevention & control*
  • Polysaccharides, Bacterial / immunology
  • Streptococcus pneumoniae / immunology*
  • United States
  • Vaccines, Conjugate / adverse effects
  • Vaccines, Conjugate / immunology
  • Vaccines, Conjugate / therapeutic use


  • 13-valent pneumococcal vaccine
  • 23-valent pneumococcal capsular polysaccharide vaccine
  • Antibodies, Bacterial
  • Pneumococcal Vaccines
  • Polysaccharides, Bacterial
  • Vaccines, Conjugate